Triple Screen Test

Know More About This Test

The Triple Marker Test is a prenatal screening test performed during the second trimester of pregnancy. It measures three substances in maternal blood—AFP, hCG, and unconjugated estriol—to assess the risk of chromosomal abnormalities and neural tube defects in the fetus.

This test estimates risk rather than providing a definitive diagnosis.

Why Is This Test Recommended?

It is recommended for pregnant women between 15 and 20 weeks of gestation, particularly those with advanced maternal age or abnormal first-trimester screening.

What Do the Results Indicate?

Abnormal marker levels may indicate increased risk of Down syndrome, Edwards syndrome, or neural tube defects.

How Is the Test Performed and Prepared For?

A blood sample is collected. No fasting is required.

Frequently Asked Questions (FAQs)

Is it mandatory?

Recommended; while not mandatory, the Triple Marker Test is strongly recommended as part of routine prenatal care for comprehensive fetal health assessment.

Does it harm the baby?

No, the test is completely safe as it only involves drawing blood from the mother with no risk to the baby.

Are results definitive?

No, this is a screening test that assesses risk probability; abnormal results require confirmatory diagnostic tests like amniocentesis or detailed ultrasound.

What follows abnormal results?

Further testing including detailed ultrasound, genetic counseling, and possibly amniocentesis or other diagnostic procedures to confirm or rule out abnormalities.

Is ultrasound needed?

Yes, ultrasound is typically performed alongside the Triple Marker Test to confirm gestational age and assess fetal anatomy for accurate interpretation.